Role of ROX Index in the first assessment of COVID-19 patients in the Emergency Department

Alice Gianstefani
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Gabriele Farina
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Veronica Salvatore
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Francesca Alva
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Maria Laura Artesiani
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Sara Bonfatti
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Francesca Campinoti
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Ilaria Caramella
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Michele Ciordinik (✉️ michele.ciordinik@studio.unibo.it)
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Andrea Lorusso
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Sara Nanni
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Daniela Nizza
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Stefano Nava
Respiratory Disease Clinic, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Fabrizio Giostra
Emergency Department, University of Bologna Hospital of Bologna Sant’Orsola-Malpighi, Bologna, Italy

Research Article
Abstract

**Background:** In Italy, since the first symptomatic cases of Coronavirus disease 2019 (COVID-19) appeared in late February 2020, 205,463 cases of Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) were reported as of April 30, causing an high rate of hospital admission through the Emergency Department (ED).

**Objectives:** The aim of the study was to evaluate the accuracy of ROX index in predicting hospitalization and mortality in patients with suspected diagnosis of COVID-19 in the ED. Secondary outcomes were to assess the number of readmissions and the variations of ROX index between first and second admission.

**Methods:** This is an observational prospective monocentric study, conducted in the ED of Policlinico Sant’Orsola-Malpighi in Bologna. We enrolled 1371 consecutive patients with suspected COVID-19 and ROX index was calculated in 554 patients. Patients were followed until hospital discharge or death.

**Results:** ROX index value < 25.7 was associated with hospitalization (AUC=0.737, 95%CI 0.696–0.779, p<0.001). ROX index < 22.3 is statistically related with higher 30-days mortality (AUC= 0.764, 95%CI 0.708-0.820, p<0.001). 8 patients were discharged and returned in the ED within the following 7 days, their mean ROX index was 30.3 (6.2; range 21.9-39.4) at the first assessment and 24.6 (5.5; 14.5-29.5) at the second assessment, (p=0.012).

**Conclusion:** ROX index, together with laboratory, imaging and clinical findings, can help discriminate patients suspected for COVID-19 requiring hospital admission, their clinical severity and their mortality risk. Furthermore, it can be useful to better manage these patients in territorial healthcare services, especially in the hypothesis of another pandemic.

Introduction

In late December 2019, clusters of severe atypical pneumonia were identified in Wuhan and in the Hubei Province of China. In Italy, since the first reports of symptomatic cases of Coronavirus disease 2019 (COVID-19) in late February 2020, 205,463 cases of Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection have been reported as of April 30, 2020. The curve of reported cases in the Italian epidemic shows a growing trend of new diagnoses until March 20, followed by a constant decrease due to government restriction. According to the indication of the World Health Organization the diagnosis is based on the positivity of real-time reverse transcription polymerase chain reaction (RT-PCR) test of oral and nasopharyngeal swabs [2], however the sensitivity and specificity are poorly characterized, and the “window period” after acquisition in which testing is most likely to produce false-negative results is not well known [3]. As a consequence, in real clinical practice also specific radiological patterns on computed tomography (CT) and on lung ultrasound are considered able to convey diagnosis and influence patient management [4].
The most frequent severe manifestation of infection appears to be interstitial pneumonia, characterized primarily by fever, cough, dyspnea, and bilateral infiltrates on chest imaging [5] with a prevalence of hypoxic respiratory failure of 19% [6, 7]. These patients may show at admission to the Emergency Department (ED) an atypical presentation of their symptoms, characterized by mild increase in respiratory rate, in face of severe hypoxia probably due to their normal or only partially impaired respiratory mechanics. This particular “phenotype” has been defined as $L$ (i.e. low elastance) versus the form closer to Acute Respiratory Distress Syndrome (ARDS), named as $H$ (i.e. high elastance). This latter been characterized by worst prognosis, and in most cases representing an evolution of phenotype $L$ [8]. At the same time, a large cohort of patients exhibits mild symptoms (myalgia, cough, fever, headache) at first presentation. Since the evolution of the disease is yet not well known with a possible sudden deterioration, one of the challenges that emergency physicians have to face is the early detection of patients who need to be hospitalized and of those who can be directly and safely discharged. This is even more important when dealing with a rapidly spreading global pandemic like COVID-19, that has the potential to overwhelm hospital capacity [9]. Hence the need of rapid and simple tools for emergency physician able to support critical clinical decisions. We tested ROX index (Respiratory rate – $O_{2}$Xygenation), which was firstly described by Roca et al in 2016 [10] as the ratio of peripheral oxygen saturation ($SpO_{2}$) and fraction of inspired oxygen ($FiO_{2}$), to Respiratory Rate (RR). ROX index was introduced to predict the need for mechanical ventilation (MV) in patients with hypoxemic acute respiratory failure (ARF) resulting from pneumonia/ARDS treated with high-flow nasal cannula (HFNC). To the best of our knowledge, the ROX index has not yet been applied in COVID-19 patients nor in patient’s initial assessment in the ED.

The primary aim of this prospective observational study was to evaluate the reliability and accuracy of the ROX index in predicting the need of hospitalization and the risk of mortality in patients with suspected diagnosis of COVID-19 as they arrive in the ED. Secondary outcomes were to assess the number of readmissions in patients initially discharged and the variations of ROX index in the time frame between first and second admission.

**Methods**

**Study design**

This is an observational prospective monocentric study, conducted in the ED of Policlinico Sant’Orsola-Malpighi in Bologna, Italy, from 13th of March to 3rd of April 2020. We enrolled 1371 consecutive patients with suspected COVID-19 admitted to the ED in a dedicated area. Symptoms such as fever, cough, dyspnea, sore throat, rhinorrhea, headache, fatigue, conjunctivitis, diarrhea, and smell or taste aberrancies were considered likely related to SARS-CoV-2 infection. The local ethics committee approved this study (551/2020/Oss/AOUBo).

**Participants**
Our analysis included patients with confirmed SARS-CoV-2 infection determined by positive result on RT-PCR test of oral and nasopharyngeal swabs, at initial test or in a repeated one during hospitalization, and patients with positive imaging findings on CT or lung ultrasound (interstitial pneumonia) but negative result on nasopharyngeal swabs test, who didn’t reach alternative diagnosis when discharged from hospital (inclusion criteria). We consider these criteria the best available in the period of enrollment based on the knowledge up to that time.

Data collection

At the time of admission to the ED, we collected demographic data, medical history and respiratory variables, such as SpO₂, FiO₂ and RR. Based on these data, ROX index was calculated using the formula: \((\text{SpO}_2/\text{FiO}_2)/\text{RR}\). National Early Warning Score 2 (NEWS2) was also calculated; it includes respiratory rate, hypercapnic respiratory failure occurrence, supplemental O₂ needing, temperature, systolic blood pressure, cardiac rate and level of consciousness [11]. Additionally, all the patients underwent arterial blood gas (ABG) analysis, and at least one imaging test (chest X-rays, lung ultrasound, and high-resolution thoracic CT). Blood tests were performed according to clinical evaluation. Patients were followed up until hospital discharge or death and medical records were extracted from the registry. The following data were extracted: hospitalization and 30-days mortality.

Statistical analysis

Demographic, clinical and laboratory characteristics of the cohort are expressed as means and standard deviation (SD) and as number and percentage as appropriated. Continuous variables were compared using ANOVA T-test or Mann-Whitney and frequencies using the chi-squared test. Areas under the curve (AUCs) and the 95% confidence interval (CI) of the receiver operator characteristic (ROC) curve were computed to predict need of hospitalization, presence of viral pneumonia and risk of 30-days mortality. The optimal ROX index cut-off was determined optimizing sensitivity and specificity, favoring sensitivity for our purposes. P-value less than 0.05 were considered significant. Statistical analysis was obtained using IBM SPSS Statistics software version 25.

Patient and public involvement

Due to the nature of pandemic crisis it was not possible to involve patients in the design, or conduct, or reporting, or dissemination plans of the study.

Results

Among 1371 patients admitted to the COVID area of our ED, we identified 554 patients who met the inclusion criteria [Figure 1].
Age was 61.5 ± 19 years, comparable to the one described in international literature [5]. In our population males represented 53.4% (N=296) and females 46.6% (N=258), which is consistent with Italian data [1]. Baseline characteristics are presented in Table 1.

**Table 1.** Baseline characteristics of the cohort (n=554).
| **Age, years** | 61.5 ± 19 |
|---------------|-----------|
| **Sex, n (%)** |           |
| Male          | 296 (53.4) |
| Female        | 258 (46.6) |
| **Comorbidities, n (%)** |           |
| Hypertension  | 204 (36.3) |
| Use of RAAS inhibitors | 52 (9.4) |
| Use of ARBs inhibitors | 55 (9.9) |
| Diabetes mellitus | 62 (11.2) |
| COPD          | 58 (10.5) |
| Asthma        | 13 (2.3) |
| Other respiratory diseases | 22 (4) |
| Ischemic heart disease | 41 (7.4) |
| Active cancer | 33 (6) |
| Chronic kidney disease | 46 (6.6) |
| Previous TIA/stroke | 26 (4.7) |
| Liver disease | 22 (4) |
| Cognitive impairment | 72 (13) |
| **Onset of symptoms, days** | 6.5 ± 5.2 |
| **Clinical features at ED admission, n (%)** |           |
| Fever         | 461 (83.4) |
| Dyspnea       | 209 (37.8) |
| Cough         | 315 (57) |
| Conjunctivitis | 8 (1.4) |
| Rhinorrhea    | 21 (3.8) |
| Sore throat   | 39 (7.1) |
| Headache      | 45 (8.1) |
| Asthenia      | 90 (16.3) |
| Myalgia/Arthralgia | 67 (12.1) |
| Diarrhea      | 81 (14.6) |
Anosmia  29 (5.2)
Ageusia/Dysgeusia  51 (9.2)
Syncope  6 (1.1)

**Respiratory rate,** breaths/min  20 ± 5
**Heart rate,** beats/min  90 ± 16
**Arterial pressure,** systolic – diastolic, mmHg  127 ± 22 – 75 ± 13
**Body temperature,** °C  37.1 ± 0.8
**SpO₂, %**  96.2 ± 3.7

Data are presented as number (n) and percentage (%) for dichotomous values or average and standard deviation for continuous values. RAAS, renin–angiotensin–aldosterone system; ARBS, angiotensin-receptor blockers; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack.

Main comorbidities were hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), chronic kidney disease, ischemic heart disease and asthma. Patients arrived at the ED 6.3 ± 5.2 days after the onset of symptoms [Table 1]. Most patients (93.7%) were neurologically normal with a 15/15 Glasgow Coma Scale (GCS). Respiratory variables registered at admission were SpO₂ (95.7% ± 3.9), RR (20 breaths/min ± 5.5) and FiO₂ (536 patients with FiO₂ 21% and 18 with FiO₂ > 21%, being this last value based on that reported on Ventimask kit used in our ED).

Laboratory findings are listed in Table 2.

**Table 2.** Laboratory tests and arterial blood gas.
| Laboratory tests                          |   |
|------------------------------------------|---|
| White Blood Count – n/mmc                | 7788 ± 5421 |
| Neutrophils – n/mmc                      | 6091 ± 6547 |
| Lymphocytes – n/mmc                      | 1673 ± 2906 |
| Eosinophils – n/mmc                      | 0.541 ± 0.1332 |
| Platelets – n/mmc                        | 221 ± 90    |
| aPTT                                     | 1.80 ± 13   |
| INR                                      | 1.2 ± 0.6   |
| Creatinine – mg/dl                       | 1.07 ± 0.99 |
| Urea – mg/dl                             | 44.2 ± 36.5 |
| Sodium – mmol/L                          | 138 ± 4.7   |
| Potassium – mmol/L                       | 4.1 ± 0.5   |
| Lactate dehydrogenase – U/L              | 288 ± 185   |
| C-Reactive Protein – mg/dl               | 6.2 ± 7.2   |
| Procalcitonin – ng/ml                    | 1.7 ± 12    |

| Arterial blood gas                        |   |
|-------------------------------------------|---|
| pH                                        | 7.42 ± 0.53 |
| PaO₂ – mmHg                               | 75 ± 20.1   |
| PaCO₂ – mmHg                              | 33.7 ± 6.6  |
| SatO₂                                     | 96 ± 4.5    |
| P/F                                       | 349.7 ± 97.2|
| HCO₃ – mmHg                               | 23.8 ± 3.3  |
| Blood Lactate – mmol/L                    | 1.2 ± 1     |

Data are presented as number (n) and percentage (%) for dichotomous values or average and standard deviation for continuous values.

In 4.9% of the admissions blood tests were not performed due to mild symptoms. Lymphopenia was present in 44% of the population. Patients often presented with normal white blood count (7788/mmc ± 5421), elevated C-reactive protein (6.2 mg/dl ± 7.2, 0.02-40.7 mg/dl) and lactate dehydrogenase (288 U/L)
± 185). In the majority of cases arterial blood gas analysis showed normal value of pH and hypocapnia [Table 2].

Viral pneumonia was confirmed at imaging in 485 patients (87.5%). ROX index in our overall population was 24.3 ± 6.5.

Baseline characteristics of the discharged and hospitalized patients are listed in Table 3.

**Table 3.** Baseline characteristic of the cohort comparing discharged and hospitalized patients.
|                                | Discharged (n=170) | Hospitalized or death (n=384) | P value |
|--------------------------------|--------------------|-------------------------------|---------|
| **Age, years**                 | 46.7 ± 14.8        | 68 ± 17                       | <0.001  |
| **Sex, n (%)**                 |                    |                               | 0.001   |
| Male                           | 72 (42.4)          | 224 (58.3)                    |         |
| Female                         | 98 (57.6)          | 160 (41.7)                    |         |
| **Comorbidities, n (%)**       |                    |                               |         |
| Hypertension                   | 23 (13.5)          | 181 (47.1)                    | <0.001  |
| Use of RAAS inhibitors         | 5 (2.9)            | 47 (12.2)                     | <0.001  |
| Use of ARBs inhibitors         | 9 (5.3)            | 46 (12)                       | 0.014   |
| Diabetes mellitus              | 8 (4.7)            | 54 (14.1)                     | 0.001   |
| COPD                           | 3 (1.8)            | 55 (14.3)                     | <0.001  |
| Asthma                         | 6 (3.5)            | 7 (1.8)                       | NS      |
| Other respiratory diseases     | 3 (1.8)            | 19 (5)                        | NS      |
| Ischemic heart disease         | 2 (1.2)            | 39 (10.2)                     | <0.001  |
| Active cancer                  | 5 (2.9)            | 28 (7.3)                      | NS      |
| Chronic kidney disease         | 1 (0.6)            | 45 (11.7)                     | <0.001  |
| Previous TIA/stroke            | 4 (2.4)            | 22 (5.7)                      | NS      |
| Liver disease                  | 3 (1.8)            | 19 (5)                        | NS      |
| Cognitive impairment           | 0 (0)              | 72 (18.8)                     | <0.001  |
| **Onset of symptoms, days**    | 7.2 ± 6.3          | 5.9 ± 4.6                     | NS      |
| **Clinical features at ED admission, n (%)** | | | |
| Fever                          | 133 (78.2)         | 328 (85.4)                    | 0.036   |
| Dyspnea                        | 53 (31.2)          | 156 (40.6)                    | 0.037   |
| Cough                          | 109 (64.1)         | 206 (53.6)                    | 0.026   |
| Conjunctivitis                 | 6 (3.5)            | 2 (0.5)                       | 0.012   |
| Rhinorrhea                     | 12 (7.1)           | 9 (2.3)                       | 0.014   |
| Sore throat                    | 26 (15.3)          | 13 (3.4)                      | <0.001  |
| Headache                       | 31 (18.2)          | 14 (3.7)                      | <0.001  |
| Asthenia                       | 33 (19.4)          | 57 (14.8)                     | NS      |
|                          | N=205 | N=189 | p-value |
|--------------------------|-------|-------|---------|
| Myalgia/Arthralgia       | 37 (21.8) | 30 (7.8) | <0.001  |
| Diarrhea                 | 32 (18.8) | 49 (12.8) | NS      |
| Anosmia                  | 21 (12.4) | 8 (2.1) | <0.001  |
| Ageusia/Dysgeusia        | 32 (18.8) | 19 (5) | <0.001  |
| Syncope                  | 1 (0.6) | 5 (1.3) | NS      |

|                          | N=205 | N=189 | p-value |
|--------------------------|-------|-------|---------|
| Respiratory rate, breaths/min | 17 ± 3 | 21 ± 6 | <0.001  |
| Heart rate, beats/min     | 88 ± 15 | 91 ± 17 | NS      |
| Arterial pressure, systolic – diastolic, mmHg | 133 ± 20 – 78 ± 11 | 125 ± 22 – 74 ± 13 | 0.001  |
| Body temperature, °C      | 36.8 ± 0.6 | 37.3 ± 0.9 | <0.001  |
| SpO2, %                   | 97.8 ± 1.6 | 94.7 ± 4.3 | <0.001  |

Data are presented as number (n) and percentage (%) for dichotomous values or average and standard deviation for continuous values. RAAS, renin–angiotensin–aldosterone system; ARBS, angiotensin-receptor blockers; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; NS, not significant.

Hospitalized patients were 69.3% (N=384): they were older and had more comorbidities than the other group. Our analysis showed that a ROX index value < 25.7 was reliable in predicting the need of hospitalization with 76.5% sensitivity and 65.6% specificity (AUC=0.737, 95%CI 0.696–0.779, p<0.001). In particular, when population was split based on age, ROX index value was 26 for patients < 65 years old (sensitivity of 71%, specificity of 60%, AUC=0.667, 95%CI 0.607–0.728, p<0.001) and 23.3 for patients ≥ 65 years old (sensitivity of 81%, specificity of 62.4%, AUC=0.764, 95%CI 0.686–0.842, p<0.001). ROC curve is represented in Figure 2A.

The accuracy of NEWS2 and RR in the prediction of hospitalization were also calculated and resulted lower than ROX index. In particular, NEWS2 sensitivity was 66% and specificity 69% (AUROC 0.736; 95%CI 0.688-0.805) whereas concerning RR sensitivity was 71% and specificity 56% (AUROC 0.692; 95%CI 0.649-0.734).

Furthermore, after 30-days follow up, 82 (14.8%) patients died after 10.35 ± 7.21 days; their age was 82.1 ± 9 (56-100), 79 patients were ≥ 65 years and 51 were males (62.2%). ROX index < 22.3 is statistically related with higher 30-days mortality, with a 74.8% sensitivity and 65.9% specificity (AUC= 0.764, 95%CI 0.708-0.820, p<0.001) [Figure 2B].
Moreover, data showed that a ROX index value < 26 was able to identify patients with viral pneumonia, as assessed at CT scan (sensitivity 62.3%, specificity 60%, AUC=0.657, 95%CI 0.595–0.719, p<0.001). Table 4 shows ROC analysis of ROX index.

Table 4. AUROC, 95%CI, P Value, Sensitivity and Specificity derived from ROC analysis of ROX index.

| Variable                  | ROX index | AUROC  | 95% CI       | p value | Sensitivity (%) | Specificity (%) |
|---------------------------|-----------|--------|--------------|---------|-----------------|-----------------|
| Hospitalization Patients < 65 y.o. | 25.7      | 0.737  | 0.696 – 0.779 | <0.001  | 76.5            | 65.6            |
| Patients ≥ 65 y.o.        | 26        | 0.667  | 0.607 – 0.728 | <0.001  | 71              | 60              |
|                           | 23.3      | 0.764  | 0.686 – 0.842 | <0.001  | 81              | 62.4            |
| 30-days mortality         | 22.3      | 0.764  | 0.708 – 0.820 | <0.001  | 74.8            | 65.9            |
| Viral pneumonia           | 26        | 0.657  | 0.595 – 0.719 | <0.001  | 62.3            | 60              |

During the entire hospitalization, 24 patients (6.25%) underwent endotracheal intubation. Their mean age was 68.7 (56-79) and 58.3% were males. Their mean ROX index just before intubation was 3.8 (range 2.5-5.71). At 30 days follow-up, 16 of them (66.7%) were alive.

Out of 554 patients, 8 patients were discharged but returned in the ED within the following 7 days and were hospitalized. Mean ROX indexes vary as follows: 30.3 (6.2; range 21.9-39.4) at the first assessment and 24.6 (5.5; 14.5-29.5) during the second assessment, p=0.012.

Discussion

In this monocentric study we suggest adding ROX index in the first ED evaluation of COVID-19 patients in order to identify cut off values able to correlate with viral pneumonia on imaging tests (CT or ultrasound). This ability is particularly important when pandemic impacts on limited ED resources, where patients suitable to underwent imaging tests have to be safely selected. In our cohort a ROX index value lower than 26 was associated with imaging findings of viral pneumonia.

Furthermore, we demonstrate that ROX index is also a simple tool able to discriminate, at admission to the ED, patients with COVID-19 infection requiring hospital admission (ROX index lower than 25.7) from those who can be safely discharged. For patients ≥ 65 years old, the cut-off value of ROX index is 23.3.
The decision regarding hospitalization in our cohort of patients was made based on the usual decision-making process used in the acute ED patient (i.e. based on multimodal elements: laboratory and imaging data, respiratory pattern, blood gas analytical data, comorbidity data and patient characteristics). The ROX cut off was then extrapolated on the group of hospitalized patients, being aware that it cannot be the only element to be used, but to be included in a broader reasoning.

Moreover, ROX index shows a good sensitivity even in COVID-19 patients who usually present a dissociation between the severity of hypoxemia and respiratory mechanics [6], often with normal RR. Additionally, ROX index of <22.3, related to 30-days mortality rate, is lower than its values for hospitalization and pneumonia findings, confirming that lower ROX index predicts a higher mortality risk. It is interesting to note that only 8 of the 170 patients discharged returned to the ED and were consequently hospitalized. In this small subset of patients, the reduction of ROX index was an indicator of worsening.

ROX index was firstly described by Roca et al in 2016 [10], in a two centers prospective observational cohort study including 157 patients with pneumonia/ARDS admitted to ICU and treated with HFNC. They showed that a ROX Index < 4.88, measured 12 hours after HFNC onset, was related to a higher risk of intubation (sensitivity of 70.1%, specificity of 72.4%). Same results were found in a following multicenter prospective observational study, built to validate the diagnostic accuracy of the index, that enrolled 191 patients with pneumonia admitted to ICU and treated with HFNC [12]; a second external validation was carried out using the FLORALI cohort study [13]. Beside its initial purpose the ROX Index was also applied as a predictor of successful HFNC weaning (cut off value > 9.2) [14] and as an indicator to titrate FiO$_2$ and set the optimal flow rates in patients with ARF treated with HFNC [15].

ROX index is an easy-to-use tool that relies on variables directly linked to oxygenation (assessed by SpO$_2$/FiO$_2$) placed in the numerator, and to respiratory distress (assessed by RR), potentially leading to pump failure, placed in the denominator, hence obtaining an additive effect, since severe patients are more likely to have lower SpO$_2$/FiO$_2$ and higher RR [10]. The variables required are non-invasive, easily and quickly obtained, as well as reproducible. Our study demonstrated the higher accuracy of ROX index compared to RR alone in the prediction of hospitalization. Moreover, we highlighted an accuracy comparable to NEWS2, a well-known score for the identification of the degree of illness in ED that however requires more variables and time to be calculated.

During COVID-19 pandemic, the main challenge has been the evaluation of a huge number of patients suffering from an unknown disease, frequently requiring hospitalization, without a proportional increase of resources and hospital capacity [9].

In this study we suggest the application of ROX index during the first assessment of COVID-19 patients in the ED, as an additional tool to help the emergency physician to evaluate the clinical severity of patients, in order to safely discharge from hospital. Our data confirm that ROX index, together with laboratory, imaging and clinical findings, can be a reliable and useful tool in the emergency setting.
To the best of our knowledge this is the first study with a large population in which ROX index is used in patients with SARS-CoV-2 infection at the admission in the ED. Moreover the majority of our population didn’t receive respiratory support and didn’t fulfill ARDS criteria [16]. This explains why our ROX index values are different from what Roca et al. [10] defined in the original study.

On the other hand, the main limits of our study are its monocentric design and the nature of the pandemic crisis. Furthermore, our data show that this is a “mild” population, it will be appropriate to evaluate whether the same results can be extended to patient populations with more severe clinical features. Indeed, we did not measure the “true” FiO$_2$ delivered to patients and we cannot exclude that air entrainment occurred, especially in patients with high respiratory demand. Further studies will be necessary to validate the use of ROX index and its cut-off values, possibly with a multicentric design.

Considering what we previously mentioned, ROX index seems to be a good combination of accuracy, non-invasivity and promptness, especially in those scenarios where the blood gas analyzer is not available. For instance, it could be used by the nursing triage to place patients at adequate priority levels, by the attribution of colors code which are directly related to the waiting time in the ED. For the same reasons we also suggest the application of ROX index in patients with COVID-19 suspicious symptoms prior the admission to the ED, such as territorial health care services, by using pulse oximetry. The expectation is to help general practitioners to better manage outpatients through a common index, especially in the unfortunate hypothesis of a further outbreak.

Declarations

Author contributions: Alice Gianstefani and Gabriele Farina designed the study, reviewed and edited the manuscript; Francesca Alvau, Maria Laura Artesiani, Sara Bonfatti, Francesca Campinoti, Ilaria Caramella, Michele Ciordinik, Andrea Lorusso, Sara Nanni and Daniela Nizza enrolled the patients, reviewed the literature, wrote the manuscript and produced the figures. Veronica Salvatore made a substantial contribution to the statistical analysis. Stefano Nava and Fabrizio Giostra reviewed and edited the manuscript. All authors read and approved the final manuscript in compliance with Ethical Standards.

Conflict of Interest: the authors declare that they have no conflict of interest.

Source of funding: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics approval: approval was obtained from the ethics committee of Bologna (Ethics approval number: 551/2020/Oss/AOUBo). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Consent: verbal informed consent was obtained prior to the interview.

References
1. Riccardo F, Andrianou X, Bella A. Epidemia COVID-19. Vol. 2020. Roma; 2020.
2. Diagnostic testing for SARS-CoV-2: interim guidance. World Health Organization 11 September 2020.
3. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020 Aug 18; 173(4):262-267. doi: 10.7326/M20-1495.
4. Peyrony O, Marbeuf-Gueye C, Truong V, Giroud M, Rivièrc E, Khenissi K, Legay L, Simonetta M, Elezi A, Principe A, Taboulet P, Ogereau C, Tourdjman M, Ellouze S, Fonatine JP. Accuracy of Emergency Department Clinical Findings for Diagnosis of Coronavirus Disease 2019. Ann Emerg Med. 2020 Oct; 76(4):405-412. doi: 10.1016/j.annemergmed.2020.05.022
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
6. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091.
7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24(1):1–3.
9. Fagiuoli S, Lorini FL, Remuzzi G; Covid-19 Bergamo Hospital Crisis Unit. Adaptations and Lessons in the Province of Bergamo. N Engl J Med. 2020 May 21;382(21):e71. doi: 10.1056/NEJMc2011599.
10. Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD, Masclans JR. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016 Oct;35:200-5. doi: 10.1016/j.jcrc.2016.05.022.
11. Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP, December 2017.
12. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376. doi: 10.1164/rccm.201803-0589OC.
13. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185–96. doi: 10.1056/NEJMoa1503326
14. Rodriguez M, Thille AW, Boissier F, Veinstein A, Chatellier D, Robert R, Le Pape S, Frat JP, Coudroy R. Predictors of successful separation from high-flow nasal oxygen therapy in patients with acute
respiratory failure: a retrospective monocenter study. Ann Intensive Care. 2019 Sep 11;9(1):101. doi: 10.1186/s13613-019-0578-8.

15. Mauri T, Carlesso E, Spinelli E, Turrini C, Corte FD, Russo R, Ricard JD, Pesenti A, Roca O, Grasselli G. Increasing support by nasal high flow acutely modifies the ROX index in hypoxemic patients: A physiologic study. J Crit Care. 2019 Oct;53:183-185. doi: 10.1016/j.jcrc.2019.06.020.

16. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.

**Figures**

![Figure 1](image)

1371 patients admitted to COVID area in ED of Policlinico Sant'Orsola Malpighi

554 patients met the inclusion criteria

- 384 hospitalized patients
- 170 discharged patients
  (8 readmitted to the ED)

**Figure 1**

Patient's enrollment flow chart.
1371 patients admitted to COVID area in ED of Policlinico Sant'Orsola Malpighi

554 patients met the inclusion criteria

- 384 hospitalized patients
- 170 discharged patients
  (8 readmitted to the ED)

**Figure 1**

Patient's enrollment flow chart.

**Figure 2**
A: Receiver operating characteristic (ROC) analysis of ROX index in predicting hospitalization (AUC 0.737; 95% CI, 0.696 – 0.779; p<0.001). B: Receiver operating characteristic (ROC) analysis of ROX index in predicting 30-days mortality (AUC 0.764; 95% CI, 0.708 – 0.820; p<0.001).

Figure 2

A: Receiver operating characteristic (ROC) analysis of ROX index in predicting hospitalization (AUC 0.737; 95% CI, 0.696 – 0.779; p<0.001). B: Receiver operating characteristic (ROC) analysis of ROX index in predicting 30-days mortality (AUC 0.764; 95% CI, 0.708 – 0.820; p<0.001).